← All trials
NCT06178679
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 2, 2024
- Primary completion
- Jun 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Dec 21, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 175
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ORA, Inc.Lead sponsor
- Stuart Therapeutics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.